Obstructive Sleep Apnea, Obesity and Cellular Adhesion Molecules: Impact of 2 Years of CPAP Treatment

Victoria M. Pak, PhD*1,2, Brendan T. Keenan, MS*1, Nicholas Jackson, MPH1, Michael A. Grandner, PhD1, Greg Maislin, MS, MA1, Richard J. Schwab, MD1,3, Erna Sif Arnardottir, MS4,5, Bryndis Benediktsdottir, MD4,5, Thorarinn Gislason, MD, PhD**1,3, Allan I. Pack, MBChB, PhD**1,3

*co-lead authors; **co-senior authors

1Center for Sleep and Circadian Neurobiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; 2Biobehavioral Research Center, School of Nursing, University of Pennsylvania, Philadelphia, PA; 3Division of Sleep Medicine/Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; 4University of Iceland, Reykjavik, Iceland; 5Landspitali Hospital, Reykjavik, Iceland

Introduction: Elevated levels of intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) may contribute to cardiovascular disease and are associated with Obstructive Sleep Apnea (OSA) and obesity. The interaction between CPAP and obesity in determining levels of these molecules is unknown.

Objectives: We investigated associations between adhesion molecule changes and CPAP usage after 2 years of treatment, and examined whether these associations differed based on obesity.

Methods: 309 OSA patients referred for CPAP from the Icelandic Sleep Apnea Cohort were studied. The mean (SD) BMI was 32.4(5.1), they had severe OSA [AHI=45.0(20.2)] and 79% were male. Subjects were stratified by BMI at baseline (<30, 30-35, ≥35). Fasting blood was drawn to assess adhesion molecules (measured via ELISA) in untreated subjects and again 2 years after CPAP initiation.

Measurements and Main Results: There were 177 full (≥4 hours/night), 44 partial (<4 hours/night), and 88 non CPAP users. We observed significant change in ICAM-1 (p<0.001) and VCAM-1 (p=0.012) change between the 3 CPAP usage groups. For ICAM-1, the strongest association was among the most obese subjects (p<0.001). In each case, we observed significant differences between full and non-users; non-users had significant increases in ICAM-1 and VCAM-1 levels compared to no change in full users.

Conclusion: In a moderate to severe OSA population, adequate CPAP usage protects against increases in cellular adhesion molecules observed in non-users over a two year period. For ICAM-1, this association is dependent on obesity, with a strong association in subjects with a BMI ≥35.